Dyne Therapeutics (DYN) Long-Term Debt Issuances (2020 - 2025)
Dyne Therapeutics (DYN) posted quarterly Long-Term Debt Issuances of $49.5 million for Q4 2025, up 77171.88% quarter-over-quarter from $64000.0 in Q4 2020.
Dyne Therapeutics (DYN) Long-Term Debt Issuances (2020 - 2025) Analysis & Trends
Dyne Therapeutics (DYN) has reported Long-Term Debt Issuances for 2 consecutive years, with $49.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to $49.5 million; the TTM figure through Dec 2025 stood at $49.5 million (up 77171.88% YoY), while the FY2025 annual figure was $148.3 million, changed N/A from the prior year.
- Long-Term Debt Issuances grew to $49.5 million in Q4 2025 per DYN's latest filing, from $64000.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $49.5 million in Q4 2025 and bottomed at $49.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -675,522.58 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 49.45 Mn |
| Dec 31, 2025 | 49.45 Mn |
| Dec 31, 2020 | 64,000.00 |
| Dec 31, 2020 | 64,000.00 |
| Mar 31, 2020 | 9.94 Mn |
| Mar 31, 2020 | 9.94 Mn |